Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received two Drug License suspension orders from drug control authorities. The first order from the Assistant Director, Drugs Control Administration, Bangalore (Karnataka) suspends the license of the Srinivasnagar Banashankari store for two days, with a potential revenue loss of about Rs 0.38 lakh. The second order from the Asst. Commissioner & Licensing Authority, Food & Drug Administration, Amravati (Maharashtra) suspends the license of the Pensionpura Paratwada store for five days, with a potential revenue loss of about Rs 1.35 lakh. Both suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940, and orders were received on May 5, 2025. The combined potential revenue impact is around Rs 1.73 lakh, which is negligible relative to the company's overall scale of operations.
The financial impact is very small (under Rs 2 lakh combined) and is unlikely to materially affect the company's earnings or stock price. However, it signals ongoing regulatory scrutiny at the store level, which investors may want to monitor for any escalation in future.